Phaseline

Targets › COX2

COX2 (Cytochrome c oxidase subunit 2): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Immunology; next expected readout May 2027.

Component of the cytochrome c oxidase, the last enzyme in the mitochondrial electron transport chain which drives oxidative phosphorylation. The respiratory chain contains 3 multisubunit complexes succinate dehydrogenase (complex II, CII), ubiquinol-cytochrome c oxidoreductase (cytochrome b-c1 complex, complex III, CIII) and cytochrome c oxidase (complex IV, CIV), that cooperate to transfer electrons derived from…. (UniProt, P00403)

Open in Phaseline: the race on COX2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Avidence TherapeuticsAVD275 Intra-articular Injection
Cyclooxygenase (COX) inhibitor
COX1, COX2Phase 1Osteoarthritis of the KneeMay 2027

Conditions

Osteoarthritis of the Knee (1)

Modalities

small molecule (1)

Companies

Avidence Therapeutics (1)

Related targets

COX1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.